Effective drug serialisation and identification is essential for improving the safety of medicines and combatting counterfeits. The Falsified Medicines Directive’s new requirements promise to crack down on the impacts of unsafe drugs. Neil Piper discusses the human cost of falsified medicines and how companies need to increase traceability of individual drug packets going forward.
The global impact of falsified medicines
The number of falsified and counterfeit medications infiltrating the supply chain has become a growing problem for global health organisations and pharmaceutical manufacturers in recent years. As a result, there have been cost implications and risks to patient safety.
The World Health Organization (WHO) references unlawful medications as substandard and falsified (SF) medical products. WHO further defines falsified medicines as “medical products that deliberately/fraudulently misrepresent their identity, composition or source.”1 According to WHO, approximately one in 10 pharmaceutical products in low- and middle-income countries are either substandard or falsified.2 As of November 2017, they reported that “twenty global medical product alerts and numerous regional warnings” had been issued, with “technical support provided in more than 100 cases.”2
Accounting for compounding factors such as the impact of loss of income to pharmaceutical companies and governments, as well as remedial expenses, it has been estimated that the cost to the European Commission equates to €950m per year.3 By 2020, it is predicted that the falsified market in Europe could be worth €3.3bn,4 highlighting the sheer scale of the problem. The financial consequences are real, but the most compelling and worrying implications arise when considering the severe level of risk to human health.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Annually, hundreds of thousands of children in lower-income countries die as a direct result of having consumed drugs for treating malaria, pneumonia and other diseases that are either substandard or falsified.5 However, high-income countries aren’t immune from the challenges of counterfeit medicines. Perhaps the most prominent news story in recent months has been the identification of a counterfeit form of the drug Xanax, which is reported to have claimed more than 200 lives in the UK and 126 in Scotland alone.6
How could standards help?
Maintaining and enhancing the integrity of the end-to-end pharmaceutical supply chain is vital to help prevent the infiltration of falsified medicines. The introduction of a standardised, unique identification system for drugs or medical devices will enable the authentication and traceability of products. This would help to combat the ability of counterfeiters to integrate their products into the healthcare supply chain. Adopting a single, global standard in healthcare would provide key supply chain stakeholders with complete visibility and the ability to track products from manufacturer to patient. The benefits would include critical patient safety and cost savings. A recent McKinsey study7 highlighted just how important standards are:
Implementing global standards across the entire healthcare supply chain could save 22,000–43,000 lives and avert 0.7 to 1.4 million patient disabilities
Rolling out standards-based systems globally could prevent tens of billions of dollars’ worth of counterfeit drugs from entering the legitimate supply chain
Healthcare costs could be reduced by $40‑$100bn globally by the implementation of global standards.
International organisations are working collaboratively to prevent counterfeits from reaching the patients. For example, Interpol Foundation, WHO and the World Customs Organization are working alongside regulators such as the US Food and Drug Administration (FDA) and the EU Commission. Collectively, they are working to raise global awareness, introducing sanctions and introducing measures to secure the supply chain.
The Falsified Medicines Directive
To ensure the integrity of the pharmaceutical supply chain, the European Union has introduced the Falsified Medicines Directive (FMD), which came into force on 9 February 2019. The rules have become mandatory for the majority of countries in the EU. Beyond Europe, the battle against falsified medicines is a worldwide struggle. Legislation is being rolled out in the US and Canada, and many countries such as Argentina, India and China already have serialisation systems in place.
The FMD integration is compulsory for any company selling or buying drugs – failure to comply means that pharmaceutical companies cannot sell their products. The directive requires the serialisation of prescribed drugs; every pack can be verified and decommissioned. If anything needs recalling, it can be identified down to the individual packet – a radical change for pharmacies and for manufacturers.
All medicinal products for human use need to have and adhere to two key safety feature requirements. The first supports the use of a single global standard, validating the comments in the McKinsey report. The second is the implementation of an anti-tampering device on a product’s packaging. In accordance with the first principle, each product package is required to carry a unique identifier,8 “a unique sequence carried by a two-dimensional barcode allowing the identification and authentication of the individual pack on which it is printed.”
What next for pharmaceutical manufacturers?
Pharmaceutical manufacturers need to consider and invest in technology that can cope with significantly different requirements from global organisations. They need to be able to report into different regulatory databases, which may have varying requirements of data to be updated at various points in the supply chain.
pharmaceutical manufacturers need to consider and invest in technology that can cope with significantly different requirements from global organisations
With every medicine receiving a different serial number, systems are needed to manage and track information related to the product and its movement. Systems infrastructure will need to be able to condense data from vast networks and upload all information to a national or European database. Each manufacturer should also ensure they have aggregation solutions in place to allow for a full track-and-trace model, as this could potentially become a requirement in Europe.
Despite the considerations and investment that must be made by pharmaceutical manufacturers, serialisation and the use of standards provide opportunities for the future. These have already been validated and are in use in the retail sector, with very tangible benefits.
Serialisation in the UK
Serialisation in the UK’s NHS system would have unprecedented benefits, particularly in acute trust settings to create a safer and more efficient service. Medications need to be tracked and traced throughout the patient pathway with ease, even to patient application. There are tangible benefits and cost savings in operational efficiencies such as the ability to automatically validate expiry dates, preventing the use or sale of expired medicines.
Identifying every product empowers healthcare professionals by allowing them to easily access accurate and transparent product information, facilitating precise ordering, improving product availability and lowering transaction costs. However, the real power comes in the ability to effortlessly identify and remove all recalled products across trusts, down to the patient level, once they have been discharged.
Conclusion
As the development of falsified medicines becomes increasingly sophisticated, the healthcare system needs to constantly evolve to ensure it has robust processes in place to reinforce the supply chain.
Global efforts are being made to transform the pharmaceutical supply chain, increasing visibility and traceability throughout. Ultimately, the aim is to reduce the risk of harm to patients. To achieve this, standards need to prove their critical worth in ensuring a seamless, lean and secure end-to-end distribution practice.
Biography
NEIL PIPER is an Auto ID expert and business consultant, with over 25 years’ experience working predominantly in the Retail and Healthcare sectors. Skilled in GS1, ISBT standards, barcode technologies (printing and scanning), RFID, EPCIS, regulatory compliance (FMD, UDI both FDA and EU MDR/IVDR, UK MHRA GS1 compliance and more). He is currently redrafting ISB 1077 and ISB 0108 standards to comply with NHS Digital requirements. He has provided consultancy to numerous NHS trusts, pharmaceutical and medical device suppliers.
References
Health Organization. (2019). Definitions of Substandard and Falsified (SF) Medical Products. [online] Available at: https://www.who.int/medicines/regulation/ssffc/definitions/en/ [Accessed 4 Jun. 2019].
int. (2019). Substandard and falsified medical products. [online] Available at: https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products [Accessed 4 Jun. 2019].
europa.eu. (2019). [online] Available at: https://ec.europa.eu/health/sites/health/files/files/pharmacos/pharmpack_12_2008/counterfeit-ia_en.pdf [Accessed 4 Jun. 2019].
eu. (2013). [online] Available at: https://eaasm.eu/public/downloads/3wxmE/Falsified+Medicines+costing+the+earth-2.pdf [Accessed 4 Jun. 2019].
BBC News. (2019). ‘Xanax’ linked to more than 200 deaths. [online] Available at: https://www.bbc.co.uk/news/health-47055499 [Accessed 4 Jun. 2019].
Susan Scutti, C. (2019). Global ‘pandemic’ of fake drugs killing children worldwide. [online] CNN. Available at: https://www.cnn.com/2019/03/11/health/fake-drugs-killing-children-study/index.html [Accessed 4 Jun. 2019].
org. (2012). [online] Available at: https://www.gs1.org/docs/healthcare/McKinsey_Healthcare_Report_Strength_in_Unity.pdf [Accessed 4 Jun. 2019].
europa.eu. (2019). [online] Available at: https://ec.europa.eu/health/sites/health/files/files/falsified_medicines/qa_safetyfeature_en.pdf [Accessed 4 Jun. 2019].
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.